Impact of chronic total occlusion recanalisation on the quality of life in patients with stable coronary artery disease

A. G. Badoian, D. A. Khelimskii, O. V. Krestyaninov, R. U. Ibragimov, R. A. Naydenov
2020 Patologiâ Krovoobrašeniâ i Kardiohirurgiâ  
<p><strong>Background</strong>. Coronary chronic total occlusion (CTO) is a common finding during routine coronary angiography. Despite significant progress in the technical success rate of CTO percutaneous coronary intervention over the last decade, indications for an invasive strategy are still controversial. To date, there is limited data on the role of invasive strategy in patients with CTO in improving the quality of life (QoL).<br /><strong>Aim</strong>. To compare the QoL changes in
more » ... QoL changes in patients with coronary artery disease with a single-vessel coronary CTO randomised to invasive or medical strategies.<br /><strong>Methods</strong>. The study included 140 symptomatic patients with single-vessel CTO, who were randomised to either invasive or medical strategies. The QoL was then analysed using the Seattle Quality of Life Questionnaire (SAQ-7), EQ-5D-5L and the Rose Dyspnea Scale at baseline, after 3 and 12 months.<br /><strong>Results</strong>. In total, 140 clinical, demographic, instrumental variables were analysed. There were no statistically significant differences between groups. At baseline, the summary score of the SAQ-7 in the medical group was 63.3 ± 15.7 and in the invasive group was −66.5 ± 13.1 (p = 0.13). The severity of dyspnoea according to the Rose questionnaire in the medical and invasive groups were 1.8 ± 1.1 and 1.9 ± 1.2, respectively, (p = 0.60). By 3 months, the summary score in the invasive group was 89.02 ± 9.2 and was statistically significantly higher than in the medical group (72.3 ± 12.4, p = 0.0001). The subscales of SAQ-7 at 3 months were also statistically significantly higher in the invasive group (p = 0.0001). This statistically and clinically significant difference between the groups persisted up to 12 months. The rate of adverse cardiovascular events was comparable in the study groups to 12 months of follow-up: 12.8% (9/70) and 7.1% (5/70) in the medical and invasive strategies, respectively. The crossover rate (from the medical to the invasive group) was 11.4% (8/70).<br /><strong>Conclusion</strong>. Our study showed that an invasive strategy should be considered as effective and safe in improving the QoL in symptomatic patients with single-vessel CTO.</p><p>Received 13 May 2020. Revised 29 May 2020. Accepted 1 June 2020.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p><p><strong>Author contributions</strong> <br />Conception and design: A.G. Badoian, O.V. Krestyaninov <br />Data collection and analysis: A.G. Badoian, D.A. Khelimskii, O.V. Krestyaninov <br />Statistical analysis: A.G. Badoian, D.A. Khelimskii, R.A. Naydenov <br />Drafting the article: A.G. Badoian, R.U. Ibragimov, D.A. Khelimskii <br />Critical revision of the article: R.U. Ibragimov, O.V. Krestyaninov, R.A. Naydenov <br />Final approval of the version to be published: A.G. Badoian, D.A. Khelimskii, O.V. Krestyaninov, R.U. Ibragimov, R.A. Naydenov</p>
doi:10.21688/1681-3472-2020-3s-43-55 fatcat:qwauygbavzhvtln6zftj4ndmje